サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541748

人工臓器と医療用バイオニクスの市場レポート：製品タイプ、用途、地域別、2024～2032年

Artificial Vital Organs and Medical Bionics Market Report by Product Type (Artificial Vital Organs, Medical Bionics), Application (Hospitals, Clinics, and Others), and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 142 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
人工臓器と医療用バイオニクスの市場レポート：製品タイプ、用途、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 142 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の人工臓器と医療用バイオニクスの市場規模は2023年に470億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに721億米ドルに達し、2024～2032年の間に4.72％の成長率（CAGR）を示すと予測しています。呼吸器疾患、肝硬変、心不全、肝不全の有病率の上昇、臓器障害を起こしやすい高齢者人口の増加、さまざまな技術の進歩が、市場を牽引する主要要因のいくつかです。

人工臓器は、しばしば人工臓器または生体人工臓器と呼ばれ、人体内の天然臓器の機能を模倣するように設計された人工装置です。これらのデバイスは、機能不全や故障した生体臓器の一時的または恒久的な代替品として機能するように開発されており、患者が必要不可欠な身体機能を維持し、場合によってはその機能を強化するのに役立っています。一方、医療用バイオニクスは、人体の機能を回復または強化するために、生物学的と人工的なコンポーネントの開発と統合に焦点を当てた、医療と工学のセグメントです。

現在、呼吸器疾患、肝硬変、心臓、腎臓、肝臓の機能不全など、さまざまな病状が顕著に急増しています。この急増は医療部門の拡大と密接に結びついており、マーケット成長の重要な触媒となっています。さらに、世界的に特に臓器関連の病気にかかりやすい高齢者人口の増加が、市場の拡大に大きく寄与しています。さらに、完全機能型人工心臓、肝臓、肺、尿道、風導管、腎臓などの革新的製品の継続的開拓が、市場力学にプラスの影響を与えています。さらに、大手市場関係者は、人工組織による臓器再生の最先端手法の導入を目指して、研究開発（R&D）に多額の投資を行っています。この継続的な技術革新が、市場の有望な展望を育んでいます。これに加えて、生存率の向上と患者の早期回復を実現するバイオ人工臓器の出現によって、人工臓器に対する需要が高まっています。このような需要の高まりは、移植への橋渡しや回復への橋渡しといった救命技術の重要な医療ケースへの導入によってさらに後押しされ、市場の成長をさらに強化しています。

人工臓器と医療用バイオニクスの市場動向/促進要因

呼吸器疾患、肝硬変、臓器不全の有病率の上昇

慢性閉塞性肺疾患（COPD）や肺感染症などの呼吸器疾患の有病率が顕著に増加しています。重症の呼吸器疾患の患者は、十分な呼吸をするために人工肺やその他の補助器具を必要とすることが多いです。さらに、過度のアルコール摂取、ウイルス性肝炎感染、非アルコール性脂肪性肝疾患など、さまざまな要因によって肝硬変を含む肝臓疾患が増加しています。肝硬変が進行すると、肝移植が必要になることもあり、人工肝臓は移植までのつなぎとして、あるいは長期的な解決策としても役立ちます。その上、心不全と肝不全は世界的に重大な健康問題です。うっ血性心不全や末期肝疾患のような病態は、高齢化、肥満、ライフスタイルの選択などの要因により増加傾向にあります。人工心臓と肝臓補助システムは、患者が移植を待つ間、あるいは恒久的な補助オプションとして、救命ソリューションを提供する上で重要な役割を果たしています。

世界の高齢者人口の増加

世界の人口動態は高齢化へとシフトしています。高齢者は自然な老化プロセスにより臓器障害にかかりやすく、人工生命臓器への介入にとって重要な人口層となっています。その上、高齢者層は心血管疾患、呼吸器疾患、腎臓疾患などの慢性的な病状に陥りやすいです。これらの疾患は、患者のQOLを管理・改善するために、人工心臓、人工肺、人工腎臓などの介入を頻繁に必要とします。ペースメーカーや人工内耳などの医療用バイオニクスもまた、加齢に伴う健康問題に対処するために高齢者によく使用されます。人工臓器と医療用バイオニクスは、こうした高齢者の生命を延長・改善し、晩年により良い生活の質を享受できるようにする上で、極めて重要なものとなっています。

さまざまな技術の進歩

医療技術の進歩により、人工臓器と医療用バイオニクスのデザイン、機能性、有効性は著しく向上しています。さらに、人工心臓や人工肺のような完全な機能を持つ人工臓器も開発され、患者はより活動的な生活を送ることができるようになりました。さらに、最先端の材料と生体工学技術の統合により、天然の臓器を忠実に模倣した生体人工臓器が開発され、拒絶反応のリスクが軽減され、患者の転帰全体が改善されています。さらに、医療技術業界の大手企業は、人工臓器と医療用バイオニクスの改良を目的とした研究開発活動に多額の投資を行っています。このような投資は、より洗練されたデバイス、強化された材料、改善された手術技術の開発につながり、これらすべてが患者の転帰改善に寄与しています。

本レポートで扱う主要質問

  • 世界の人工臓器と医療用バイオニクスの市場の市場規模は？
  • 2024～2032年における人工臓器と医療用バイオニクスの市場の成長率は？
  • 世界の人工臓器と医療用バイオニクスの市場を牽引する主要因は何か？
  • 世界の人工臓器と医療用バイオニクスの市場に対するCOVID-19の影響は？
  • 世界の人工臓器と医療用バイオニクスの市場の製品タイプ別内訳は？
  • 世界の人工臓器と医療用バイオニクスの市場における主要地域は？
  • 世界の人工臓器と医療用バイオニクスの市場における主要参入企業/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の人工臓器と医療用バイオニクス市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品タイプ別

  • 人工生命維持装置
    • 市場動向
    • 主要セグメント
      • 人工肝臓
      • 人工心臓
      • 人工膵臓
      • 人工腎臓
      • 人工肺
      • 酸素供給装置
    • 市場予測
  • 医療バイオニクス
    • 市場動向
    • 主要セグメント
      • バイオニック・リムス
      • ビジョンバイオニクス
      • イヤーバイオニクス
      • 外骨格
      • ブレインバイオニクス
      • 心臓弁
      • 心臓バイオニクス
    • 市場予測

第7章 市場内訳：用途別

  • 病院
  • クリニック
  • その他

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abiomed
    • BiVACOR Inc
    • CARMAT
    • Cirtec Medical
    • Edwards Lifesciences
    • Ekso Bionics Holdings Inc.
    • Nikkiso Co. Ltd.
    • Second Sight Medical Products Inc
    • SynCardia Systems LLC（Picard Medical Inc.）
図表

List of Figures

  • Figure 1: Global: Artificial Vital Organs and Medical Bionics Market: Major Drivers and Challenges
  • Figure 2: Global: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Artificial Vital Organs and Medical Bionics Market: Breakup by Product Type (in %), 2023
  • Figure 5: Global: Artificial Vital Organs and Medical Bionics Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Artificial Vital Organs and Medical Bionics Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Artificial Vital Organs and Medical Bionics (Artificial Vital Organs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Artificial Vital Organs and Medical Bionics (Artificial Vital Organs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Artificial Vital Organs and Medical Bionics (Medical Bionics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Artificial Vital Organs and Medical Bionics (Medical Bionics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Artificial Vital Organs and Medical Bionics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Artificial Vital Organs and Medical Bionics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Artificial Vital Organs and Medical Bionics (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Artificial Vital Organs and Medical Bionics (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Artificial Vital Organs and Medical Bionics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Artificial Vital Organs and Medical Bionics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: North America: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: North America: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: United States: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: United States: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Canada: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Canada: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Asia-Pacific: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Asia-Pacific: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: China: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: China: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Japan: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Japan: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: India: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: India: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: South Korea: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: South Korea: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Australia: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Australia: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Indonesia: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Indonesia: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Others: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Others: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Europe: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Europe: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Germany: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Germany: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: France: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: France: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: United Kingdom: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: United Kingdom: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Italy: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Italy: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Spain: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Spain: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Russia: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Russia: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Others: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Others: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Latin America: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Latin America: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Brazil: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Brazil: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Mexico: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Mexico: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Middle East and Africa: Artificial Vital Organs and Medical Bionics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Middle East and Africa: Artificial Vital Organs and Medical Bionics Market: Breakup by Country (in %), 2023
  • Figure 65: Middle East and Africa: Artificial Vital Organs and Medical Bionics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Global: Artificial Vital Organs and Medical Bionics Industry: SWOT Analysis
  • Figure 67: Global: Artificial Vital Organs and Medical Bionics Industry: Value Chain Analysis
  • Figure 68: Global: Artificial Vital Organs and Medical Bionics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Artificial Vital Organs and Medical Bionics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Artificial Vital Organs and Medical Bionics Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Artificial Vital Organs and Medical Bionics Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Artificial Vital Organs and Medical Bionics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Artificial Vital Organs and Medical Bionics Market: Competitive Structure
  • Table 6: Global: Artificial Vital Organs and Medical Bionics Market: Key Players
目次
Product Code: SR112024A6458

The global artificial vital organs and medical bionics market size reached US$ 47.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 72.1 Billion by 2032, exhibiting a growth rate (CAGR) of 4.72% during 2024-2032. The rising prevalence of respiratory ailments, cirrhosis, and heart and liver failures, the increasing geriatric population that is highly prone to organ disorders, and various technological advancements represent some of the key factors driving the market.

Artificial vital organs, often referred to as artificial organs or bioartificial organs, are man-made devices designed to mimic the functions of natural organs within the human body. These devices are developed to serve as temporary or permanent replacements for malfunctioning or failed biological organs, helping patients maintain essential bodily functions and, in some cases, even enhancing them. On the other hand, medical bionics is a field of medical science and engineering that focuses on the development and integration of biological and artificial components to restore or enhance the functioning of the human body.

Currently, there is a notable surge in the prevalence of various medical conditions, including respiratory disorders, cirrhosis, as well as heart, kidney, and liver failures. This surge is closely tied to the expanding healthcare sector and serves as a significant catalyst for market growth. Furthermore, the increasing elderly population, which is particularly susceptible to organ-related ailments worldwide, is making a substantial contribution to the market's expansion. Moreover, the continuous development of innovative products, such as fully functional artificial hearts, livers, lungs, urethras, windpipes, and kidneys, is exerting a positive impact on market dynamics. Additionally, major market players are making substantial investments in research and development (R&D) endeavors, aimed at introducing cutting-edge methods of organ regeneration through engineered tissues. This ongoing innovation is fostering a promising outlook for the market. Besides this, there is a rising demand for artificial organs, driven by the emergence of bioartificial organs that offer improved survival rates and faster patient recovery. This growing demand is further propelled by the implementation of life-saving technologies like the bridge to transplant and the bridge to recovery in critical medical cases, further reinforcing market growth.

Artificial Vital Organs and Medical Bionics Market Trends/Drivers:

Rising prevalence of respiratory ailments, cirrhosis, and organ failures

There has been a notable increase in the prevalence of respiratory ailments such as chronic obstructive pulmonary disease (COPD) and lung infections. Patients with severe respiratory issues often require artificial lungs or other assistive devices to breathe adequately. Moreover, liver diseases, including cirrhosis, have seen a rise due to various factors like excessive alcohol consumption, viral hepatitis infections, and non-alcoholic fatty liver disease. In advanced stages, cirrhosis may necessitate liver transplantation, and artificial livers can serve as a bridge to transplantation or even a long-term solution. Besides, heart and liver failures are significant health concerns worldwide. Conditions like congestive heart failure and end-stage liver disease are on the rise due to factors such as an aging population, obesity, and lifestyle choices. Artificial hearts and liver support systems play a crucial role in providing life-saving solutions while patients await transplantation or as a permanent support option.

Increasing geriatric population across the globe

The global demographic landscape is shifting toward an aging population. Elderly individuals are more susceptible to organ disorders due to the natural aging process, making them a key demographic for artificial vital organ interventions. Besides, the elderly population is more prone to chronic medical conditions, including cardiovascular diseases, respiratory ailments, and kidney disorders. These conditions frequently require interventions such as artificial hearts, lungs, or kidneys to manage or improve the patient's quality of life. Medical bionics, such as pacemakers and cochlear implants, are also commonly used in elderly individuals to address age-related health issues. Artificial vital organs and medical bionics become crucial in extending and improving the lives of these elderly individuals, allowing them to enjoy a better quality of life in their later years.

Various technological advancements

Advancements in medical technology have significantly improved the design, functionality, and effectiveness of artificial vital organs and medical bionics. Moreover, full-functioning artificial organs, such as artificial hearts and lungs, have been developed with enhanced capabilities, allowing patients to lead more active lives. Besides, the integration of cutting-edge materials and bioengineering techniques has led to the creation of bioartificial organs that closely mimic natural organs, reducing the risk of rejection and improving overall patient outcomes. Additionally, leading players in the medical technology industry are investing heavily in research and development activities aimed at improving artificial vital organs and medical bionics. These investments result in the development of more sophisticated devices, enhanced materials, and improved surgical techniques, all of which contribute to better patient outcomes.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global artificial vital organs and medical bionics market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product type and application.

Breakup by Product Type:

Artificial Vital Organs

Artificial Liver

Artificial Heart

Artificial Pancreas

Artificial Kidney

Artificial Lungs

Oxygenators

Medical Bionics

Bionic Limbs

Vision Bionics

Ear Bionics

Exoskeletons

Brain Bionics

Heart Valves

Cardiac Bionics

Artificial vital organs represent the most used product type

The report has provided a detailed breakup and analysis of the market based on the product type. This includes artificial vital organs (artificial liver, artificial heart, artificial pancreas, artificial kidney, artificial lungs, and oxygenators) and medical bionics (bionic limbs, vision bionics, ear bionics, exoskeletons, brain bionics, heart valves, and cardiac bionics). According to the report, artificial vital organs represented the largest segment.

Artificial vital organs are designed to mimic the functions of natural vital organs such as the heart, lungs, kidneys, and liver. These devices are often used as a last resort when a patient's natural organs fail. They serve a life-saving function, providing crucial support to sustain a patient's life until a transplant becomes available or the natural organs recover. Moreover, there is a consistently high demand for artificial vital organs due of the prevalence of organ failure and the limited availability of organ donors. Individuals worldwide suffer from conditions that can lead to organ failure, and the demand for replacement organs far exceeds the supply. Artificial vital organs bridge this gap by offering a viable solution to patients in critical need.

Breakup by Application:

Hospitals

Clinics

Others

A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes hospitals, clinics, and others.

Hospitals are a primary application for artificial vital organs and medical bionics. In these healthcare facilities, artificial vital organs such as artificial hearts, lungs, and kidneys are often used to support patients with organ failure while they await transplants. Additionally, medical bionics, including devices like cochlear implants and bionic limbs, may be provided to patients in hospital settings to improve their quality of life and functional capabilities.

Clinics, including specialized medical centers and outpatient facilities, play a crucial role in the application of artificial vital organs and medical bionics. These settings are where patients may receive diagnosis, consultation, and follow-up care related to these advanced medical technologies. Clinics often offer services related to the assessment, fitting, and maintenance of medical bionics, making them essential in the continuum of care.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America, particularly the United States and Canada, boasts a highly advanced healthcare infrastructure with state-of-the-art medical facilities and research institutions. This infrastructure fosters innovation and the development of cutting-edge medical technologies, including artificial vital organs and medical bionics. Besides, the region is a global hub for medical research and development. Leading universities, medical centers, and private companies collaborate to push the boundaries of medical science. This collaborative environment accelerates the creation and commercialization of medical bionics and artificial vital organs. Moreover, the region has well-established regulatory bodies, such as the Food and Drug Administration (FDA) in the United States and Health Canada, which ensure the safety and efficacy of medical devices. A robust regulatory framework provides confidence to investors, manufacturers, and healthcare providers, encouraging the development and adoption of medical bionics.

Competitive Landscape:

The competitive landscape of the market is characterized by the presence of multiple players that include established brands, emerging startups, and specialty manufacturers. Presently, leading companies are heavily investing in R&D to develop innovative and advanced artificial vital organs and medical bionics. They focus on improving the performance, durability, and safety of these devices, as well as reducing their size and enhancing compatibility with the human body. They are also expanding their product portfolios to cover a broader range of medical bionics and artificial organs. This diversification allows them to address a wider array of medical conditions and patient needs. Besides, companies are acquiring or merging with other companies in the industry to expand capabilities, gain access to new technologies, and increase market share.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abiomed

BiVACOR Inc

CARMAT

Cirtec Medical

Edwards Lifesciences

Ekso Bionics Holdings Inc.

Nikkiso Co. Ltd.

Second Sight Medical Products Inc

SynCardia Systems LLC (Picard Medical Inc.)

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Recent Developments:

Edwards LifeSciences Corporation invested $35 million in an exclusive right to acquire Corvia Medical, Inc., the developer of the world's first transcatheter device designed to treat heart failure with preserved or mid-range ejection fraction.

In February 2020, Ekso Bionics Holdings, Inc. teamed up with Kindred Healthcare, LLC to test EksoNR, a robotic exoskeleton, in their long-term acute care hospitals.

Key Questions Answered in This Report

  • 1. How big is the global artificial vital organs and medical bionics market?
  • 2. What is the expected growth rate of the global artificial vital organs and medical bionics market during 2024-2032?
  • 3. What are the key factors driving the global artificial vital organs and medical bionics market?
  • 4. What has been the impact of COVID-19 on the global artificial vital organs and medical bionics market?
  • 5. What is the breakup of the global artificial vital organs and medical bionics market based on the product type?
  • 6. What are the key regions in the global artificial vital organs and medical bionics market?
  • 7. Who are the key players/companies in the global artificial vital organs and medical bionics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Artificial Vital Organs and Medical Bionics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Artificial Vital Organs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Artificial Liver
      • 6.1.2.2 Artificial Heart
      • 6.1.2.3 Artificial Pancreas
      • 6.1.2.4 Artificial Kidney
      • 6.1.2.5 Artificial Lungs
      • 6.1.2.6 Oxygenators
    • 6.1.3 Market Forecast
  • 6.2 Medical Bionics
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Bionic Limbs
      • 6.2.2.2 Vision Bionics
      • 6.2.2.3 Ear Bionics
      • 6.2.2.4 Exoskeletons
      • 6.2.2.5 Brain Bionics
      • 6.2.2.6 Heart Valves
      • 6.2.2.7 Cardiac Bionics
    • 6.2.3 Market Forecast

7 Market Breakup by Application

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Clinics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abiomed
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 BiVACOR Inc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 CARMAT
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Cirtec Medical
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 Edwards Lifesciences
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Ekso Bionics Holdings Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
    • 13.3.7 Nikkiso Co. Ltd.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Second Sight Medical Products Inc
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 SynCardia Systems LLC (Picard Medical Inc.)
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 SWOT Analysis